Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
A 26-year-old male developed narcoleptic-like episodes while on pegylated interferon-alpha 2b (peg-IFN-α2b) therapy for stage IIIB melanoma. Once peg-IFN-α2b was discontinued, the narcoleptic-like episodes eradicated. A case report and review of the literature are presented in this article.
Honor Health Internal Medicine, Scottsdale Thompson Peak Medical Center, Scottsdale, AZ, U.S.A.
Benjamin O
BO
Lawson
Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, U.S.A. hung.khong@hci.utah.edu.
Hung T
HT
Khong
D000328:Adult; D004252:DNA Mutational Analysis; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009290:Narcolepsy / Q000150:complications*; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*; D013575:Syncope
D006680:HLA Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b
Pegylated IFN-α2b; loss of consciousness; melanoma; narcolepsy; syncope